文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

旋转屏蔽近距离放疗在前列腺癌剂量升级与尿道保护中的有效性

Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-08-06

该计划研究纳入26例患者,比较单次153Gd旋转屏蔽近距离放疗(RSBT)与常规192Ir高剂量率近距离放疗(HDR-BT),放射生物学建模计入剂量率和相对生物效应。结果显示RSBT可在不增加尿道剂量的前提下提高PTV EQD290%,或不降低PTV剂量的前提下降低尿道D10%,代价是治疗时间延长;源衰变后RSBT获益减小,但1个半衰期后仍理论上优于HDR-BT超过20%。

要点

  • RSBT剂量升级使PTV EQD290%提高42.5%±8.4%而不增加尿道D10%,治疗时间216.8±28.9分钟 vs 15.1±2.1分钟。
  • RSBT尿道保护使尿道D10%降低26.0%±3.4%而不降低PTV EQD290%,治疗时间133.6±16.5分钟 vs 12.0±1.7分钟。
  • 1个半衰期后RSBT获益减小,但理论上仍优于HDR-BT超过20%。

核心结论

  • RSBT相对于HDR-BT可提高PTV EQD90%或降低尿道D10%,代价是治疗时间增加。
  • 源衰变会减小RSBT获益,但1个半衰期后RSBT理论上仍优于HDR-BT超过20%。

研究设计与样本

  • 计划研究,纳入26例患者,比较单次153Gd RSBT与常规192Ir HDR-BT。
  • PTV剂量以2 Gy分次等效剂量(EQD2)表示,计入相对生物效应(192Ir为1.00,153Gd为1.15)、剂量延长(修复半衰期114分钟)和肿瘤剂量反应(α/β为3.41 Gy)。
  • HDR-BT处方使90% PTV接受处方剂量的110%,剂量升级处方19 Gy对应EQD290%为93.9 GyEQD2,尿道保护处方15 Gy对应EQD290%为60.7 GyEQD2。
  • 建模使用20个90.95 GBq 153Gd RSBT源和1个370 GBq 192Ir HDR-BT源。

主要发现

  • 新鲜源剂量升级时,RSBT使PTV EQD290%提高42.5%±8.4%而不增加尿道D10%,治疗时间216.8±28.9分钟 vs 15.1±2.1分钟。
  • 1个半衰期后(153Gd为240.4天,192Ir为73.8天),EQD290%提高20.5%±9.1%。
  • 新鲜源尿道保护时,RSBT使尿道D10%降低26.0%±3.4%而不降低PTV EQD290%,治疗时间133.6±16.5分钟 vs 12.0±1.7分钟。
  • 1个半衰期后,尿道D10%降低20.2%±4.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare single-fraction 153Gd-based rotating shield brachytherapy (RSBT) for prostate cancer with conventional 192Ir-based high-dose-rate brachytherapy (HDR-BT) in a planning study that radiobiologically accounts for dose rate and relative biological effectiveness. RSBT was used for planning target volume (PTV) dose escalation without increasing urethral dose for monotherapy, or for urethral sparing without decreasing PTV dose as a boost to external beam radiation therapy. METHODS AND MATERIALS: Twenty-six patients were studied. PTV doses were expressed as equivalent dose delivered in 2 Gy fractions (EQD2), accounting for relative biological effectiveness (1.00 for 192Ir and 1.15 for 153Gd), dose protraction (114-minute repair half-time), and tumor dose response (α/β of 3.41 Gy). HDR-BT dose was prescribed such that 90% of the PTV received 110% of the prescription dose of 19 Gy for dose escalation and 15 Gy for urethral sparing, corresponding to EQD290% values (minimum EQD2 to the hottest 90% of the PTV) of 93.9 GyEQD2 and 60.7 GyEQD2, respectively. Twenty 90.95 GBq 153Gd RSBT sources and one 370 GBq 192Ir HDR-BT source were modeled. RESULTS: For dose escalation with fresh sources, RSBT increased PTV EQD290% by 42.5% ± 8.4% (average ± standard deviation) without increasing urethral D10%, with treatment times of 216.8 ± 28.9 minutes versus 15.1 ± 2.1 minutes. After 1 half-life (240.4 days for 153Gd and 73.8 days for 192Ir), EQD290% increased 20.5% ± 9.1%. For urethral sparing with fresh sources, RSBT decreased urethral D10% by 26.0% ± 3.4% without decreasing PTV EQD290%, with treatment times of 133.6 ± 16.5 minutes versus 12.0 ± 1.7 minutes. After 1 half-life, urethral D10% decreased 20.2% ± 4.8%. CONCLUSIONS: RSBT can increase PTV EQD90% or decrease urethral D10% relative to HDR-BT at the cost of increased treatment time. Source aging reduces RSBT benefit, but RSBT remains theoretically superior to HDR-BT by >20% after 1 half-life has elapsed.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Adams Q, Hopfensperger KM, Kim Y, et al. Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing. Int J Radiat Oncol Biol Phys. 2018. PMID: 30092333. doi:10.1016/j.ijrobp.2018.07.2015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。